Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship

AAPS Journal

Volumn 16, Issue 2, 2014, Pages 258-268

  Wang, Hong Jaan ^a   Pao, Li Heng ^a,b   Hsiong, Cheng Huei ^a   Shih, Tung Yuan ^a   Lee, Meei Shyuan ^a   Hu, Oliver Yoa Pu ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

bioavailability; CYP2C; flavonoid; structure activity relationship; tamarixetin

Indexed keywords

4 HYDROXYTOLBUTAMIDE; CYTOCHROME P450 2C; CYTOCHROME P450 INHIBITOR; FLAVONOID; FLUINDOSTATIN; TAMARIXETIN; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; GLYCOSYLATION; HYDROXYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUALITATIVE ANALYSIS; QUALITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DIET; DISACCHARIDES; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; FLAVONOIDS; INDOLES; MALE; MICROSOMES, LIVER; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUERCETIN; RATS; RATS, WISTAR; TOLBUTAMIDE;

EID: 84895860767     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9549-4     Document Type: Article

References (47)

1. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23. (Pubitemid 40558141)
2. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev. 2003;35:35-98. (Pubitemid 36249785)
3. Foster BC, Arnason JT, Briggs CJ. Natural health products and drug disposition. Annu Rev Pharmacol Toxicol. 2005;45:203-26. (Pubitemid 40261803)
4. Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJD. Herbal bioactivation: the good, the bad and the ugly. Life Sci. 2004;74:935-68. (Pubitemid 37522131)
5. Boumendjel A, Pietro AD, Dumontet C, Barron D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev. 2002;22:512-29.
6. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab. 2006;7:729-44. (Pubitemid 44509679)
7. Cermak R. Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Metab Toxicol. 2008;4:17-35. (Pubitemid 351234098)
8. Mullie P, Clarys P, Deriemaeker P, Hebbelinck M. Estimation of daily human intake of food flavonoids. Int J Food Sci Nutr. 2008;59:291-8. (Pubitemid 351584065)
9. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130(Suppl):2073-85.
10. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol in Vitro. 2006;20:187-210. (Pubitemid 43087702)
11. Krishna D, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994;26:144-60. (Pubitemid 24064238)
12. Rendic S, di Carlo FJ. Human cytochrome P450s enzymes: a status report summarizing their reactions, substances, inducers, and inhibitors. Drug Metab Rev. 2001;29:413-580. (Pubitemid 27293618)
13. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450s enzymes involved in the oxidation of drugs, carcinogens and toxic chemical: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-23. (Pubitemid 24229655)
14. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Brit J Clin Pharmacol. 2001;52:349-55. (Pubitemid 32939439)
15. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003;43:84-91. (Pubitemid 36015447)
16. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54:1257-70. (Pubitemid 35284252)
17. Kruijtzer CMF, Beijnen JH, Schellens JHM. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist. 2002;7:516-30. (Pubitemid 36009000)
18. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43:149-73. (Pubitemid 37372638)
19. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in human. II. Review of 93 intervention studies. Am J Clin Nutr. 2005;81 Suppl 1:243-55.
20. Kim JY, Lee S, Kim DH, Kim BR, Park R, Lee BM. Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes. J Toxicol Environ Health A. 2002;65:373-81. (Pubitemid 34264153)
21. Quintieri L, Bortolozzo S, Straliotto S, Moro S, Pavanetto M, Nassi A, et al. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug Metab Pharmacokinet. 2010;25:466-76.
22. Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol. 2010;48:429-35.
23. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450s probe substrates commonly used by the pharmaceutical industry to study in vitro drug interaction. Drug Metab Dispos. 2002;30:1311-9. (Pubitemid 35397032)
24. Toda T, Eliasson E, Ask B, Inotsume N, Rane A. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009;105:327-32.
25. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40:263-81. (Pubitemid 32458153)
26. Sheu MT, Liou YB, Kao YH, Lin YK, Ho HO. A quantitative structure-activity relationship for the modulation effects of flavonoids on P-glycoprotein-mediated transport. Chem Pharm Bull. 2010;58:1187-94.
27. Pao LH, Hu OYP, Fan HY, Lin CC, Liu LC, Huang PW. Herb-drug interaction of 50 Chinese herbal medicines on CYP3A4 activity in vitro and in vivo. Am J Chin Med. 2012;40:57-73.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-75.
29. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P450 dependent xenobiotic oxidations. Biochem Pharmacol. 1988;37:1137-44. (Pubitemid 18066470)
30. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol. 1998;45:107-14. (Pubitemid 28045676)
31. Toreson H, Eriksson BM. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection. J Chromatogr A. 1996;729:13-8. (Pubitemid 26135002)
32. Kitagawa S. Inhibitory effects of polyphenols on P-glycoprotein-mediated transporter. Biol Pharm Bull. 2006;29:1-6. (Pubitemid 43036683)
33. Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, et al. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol. 2010;23:1921-35.
34. Lorenz M, Wessler S, Follmann E, Michaelis W, Dusterhoft T, Baumann G, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2004;279:6190-5. (Pubitemid 38220652)
35. Sherry Chow HH, Hakim I, Vining D, Crowell J, Cordova C, Chew W, et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006;15:2473-6. (Pubitemid 46048307)
36. Nielsen SE, Breinholt V, Justesen U, Cornett C, Dragsted LO. In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica. 1998;29:389-401. (Pubitemid 28207043)
37. Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brosen K, Friedberg T. In vitro investigation of cytochrome P450s-mediated metabolism of dietary fl avonoids. Food Chem Toxicol. 2002;40:609-16. (Pubitemid 34310426)
38. Wright B, Moraes LA, Kemp CF, Mullen W, Crozier A, Lovegrove JA, et al. A structure basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br J Pharm. 2010;159:1312-25.
39. Walle T. Absorption and metabolism of flavonoids. Free Radic Biol Med. 2004;36:829-37. (Pubitemid 38401062)
40. Lan K, Jiang XH, He JL. Quantitative determination of isorhamnetin, quercetin and kaempferol in rat plasma by liquid chromatography with electrospray ionization tandem mass spectrometry and its application to the pharmacokinetic study of isorhamnetin. Rapid Commun Mass Spectrom. 2007;21:112-20. (Pubitemid 46095469)
41. Si D, Wang Y, Zhou YH, Guo Y, Wang J, Zhou H, et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos. 2008;37:629-34.
42. Dohadwala MM, Holbrook M, Hamburg NM, Shenouda SM, Chung WB, Titas M, et al. Effects of cranberry juice consumption on vascular function in patients with coronary artery disease. Am J Clin Nutr. 2011;93:934-40.
43. Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E782-92.
44. Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE. A prospective study of dietary flavonoids intake and incidence of epithelial ovarian cancer. Int J Cancer. 2007;121:2225-32. (Pubitemid 47585602)
45. Egert S, Rimbach G. Which sources of flavonoids: complex diets or dietary supplements? Adv Nutr. 2011;2:8-14.
46. Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, et al. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Method. 2010;20:452-7.
47. Pan-Zhou XR, Cretton-Scott E, Zhou XJ, Yang MX, Lasker JM, Sommadossi JP. Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3′-azido-3′-deoxythymidine (AZT) to 3′-amino-3′- deoxythymidine. Biochem Pharmacol. 1998;55:757-66. (Pubitemid 28329338)